- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05847257
Impact of Co Enzyme Q10 as Adjuvant Therapy to Letrozole on Spermiogram
Impact of Co Enzyme Q10 as Adjuvant Therapy to Letrozole on Spermiogram and Sex Hormone in Iraqi Infertile Men; A Comparative Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We will evaluate the impacts of adding coenzyme Q10 to letrozole on spermiogram and sex hormone in men diagnosed with idiopathic oligo/astheno/ teratozoospermia (iOAT) syndrome.
The study will include 67 patients which will be randomly separated into two groups, Group (A) 29 patients will be treated with letrozole 2.5mg tablet orally twice a week, Group (B) 38 patient will be treated with a combination of letrozole 2.5 mg tablet orally twice a week plus Co-Q10 400mg per day, both groups complete treatment for three months. Semen sample, serum FSH, estradiol (E2), and testosterone (T) were analyzed at day one, and at the end of one, two, and three months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Baghdad, Iraq, 12221
- specialized center of infertility/ Nahrain University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult male patients.
- Aged 18 - 60 years.
- Confirmed diagnosis with idiopathic Oligo-Astheno-Teratozoospermia (iOAT) syndrome.
Exclusion Criteria:
- Patients who have been found to have additional infertility causes, such as varicocele or Obstruction of the ejaculatory duct.
- Those who have had surgery for male factor infertility.
- Patients with infections such as STD.
- Patient with renal or liver disease
- Incomplete patient data
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Group A
group A (29) patients received letrozole 2.5mg twice weekly for 3 months
|
letrozole 2.5mg twice weekly for 3 months
|
Experimental: Group B
Group B (38) patients receive letrozole 2.5mg twice a week plus Co Q10 400 mg per day for 3 months
|
letrozole 2.5mg twice weekly for 3 months
Coenzyme Q10 400 mg per day for 3 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The seminal fluid analysis
Time Frame: change in value from baseline to the end of 1st, 2nd and 3rd month for three consecutive months of treatment
|
sperm volume/ ml, Sperm concentration/ml, Total sperm count / ml, Progressive Sperm motility (%), Non-progressive Sperm motility (%), Immotile Sperm (%), Normal Sperm morphology (%)
|
change in value from baseline to the end of 1st, 2nd and 3rd month for three consecutive months of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
hormone profile
Time Frame: change in value from baseline to the end of 1st, 2nd and 3rd month for three consecutive months of treatment
|
concentration of Serum FSH, concentration of Serum estradiol, and concentration of Serum testosterone
|
change in value from baseline to the end of 1st, 2nd and 3rd month for three consecutive months of treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infertility
- Infertility, Male
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Micronutrients
- Hormone Antagonists
- Vitamins
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
- Coenzyme Q10
- Ubiquinone
Other Study ID Numbers
- 2023M01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infertility, Male
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMale Infertility, AzoospermiaUnited States
-
Assuta Hospital SystemsMaccabi Healthcare Services, IsraelCompletedInfertility, Female Infertility, Male InfertilityIsrael
-
Reproductive Medicine Associates of New JerseyTerminated
-
Jinling Hospital, ChinaRecruitingMale Infertility Due to HypospermatogenesisChina
-
Sapientiae InstituteTerminated
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedPregnancy | Male Infertility | Female InfertilityNetherlands
-
Gazi UniversityCompletedMale Infertility | Unexplained Infertility
-
Hillel Yaffe Medical CenterUnknownMale Infertility With Severe Oligo-terato-asteno-spermiaIsrael
-
Assiut UniversityNot yet recruitingMale Infertility Due to Azoospermia
-
Universitair Ziekenhuis BrusselRecruitingMale InfertilityBelgium
Clinical Trials on Letrozole tablets
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Mylan Pharmaceuticals IncCompleted
-
Mylan Pharmaceuticals IncCompleted
-
EgymedicalpediaCompletedPCOS (Polycystic Ovary Syndrome) of Bilateral OvariesEgypt
-
Zagazig UniversityActive, not recruitingGestational Trophoblastic DiseaseEgypt
-
Tolmar Inc.RecruitingBreast CancerUnited States, Mexico, Brazil, Canada, Puerto Rico, Argentina
-
Tolmar Inc.Enrolling by invitationBreast CancerUnited States, Puerto Rico
-
Zagazig UniversityCompleted
-
Queen Mary Hospital, Hong KongQueen Elizabeth Hospital, Hong Kong; Prince of Wales Hospital, Shatin, Hong... and other collaboratorsRecruiting
-
Centre of Clinical Pharmacology, Hanoi Medical...Not yet recruitingIrritable Bowel Syndrome With DiarrheaVietnam